Dubai, UAE – April 23, 2025 – Meta Cell Technology (MCT) has reached a significant milestone at the Dubai Derma 2025 conference. The event, held from April 14 to 16 at the Dubai World Trade Centre, showcased MCT’s innovative approach to enhancing autologous therapies through MCT Technology.
MCT’s cutting-edge system utilizes photothermal biomodulation to promote the release of autologous exosomes, growth factors, and ATP from autologous samples.This advancement provides clinicians with a safe and effective tool to enhance therapeutic outcomes across multiple medical disciplines, including aesthetic medicine, clinical dermatology, regenerative medicine, gynecology, and more. At the Congress, MCT was joined by its official distributor in the UAE, Technoo Med. The collaboration provided an opportunity to discuss future strategic synergies and explore ways to expand the reach of MCT’s innovative therapies in the region.
Philippe Plan, CEO of Meta Cell Technology, emphasized the company’s commitment to scientific exchange and innovation, stating:
“Our commitment is to be present at scientific meetings to exchange scientific knowledge and provide doctors, partners, and healthcare professionals with effective and safe technological tools to enhance clinical practice within the field of regenerative medicine.”
MCT’s participation in Dubai Derma 2025 underscores its dedication to advancing regenerative medicine and fostering collaborations that drive innovation in healthcare.
